Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Samuel Yoselevitz

Gastroenterology Virginia Beach, VA Medical Doctor

NPI 1336279884 CMS profile 15060

1101 First Colonial Rd, Suite 400, Virginia Beach, VA 23454

Open in the dashboard

General payments

$6,399

301 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Samuel Yoselevitz of Virginia Beach, VA is reported in the CMS Open Payments database as having received $6,399 across 301 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,134 54
2024 General $1,378 61
2023 General $1,225 62
2022 General $1,199 56
2021 General $622 33
2020 General $371 19
2019 General $469 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samuel Yoselevitz
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Samuel Yoselevitz were reported at $1,134. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Samuel Yoselevitz Gastroenterology median Middle half National median
2019 $469 $417 $126–$1,100 $163
2020 $371 $224 $74–$624 $114
2021 $622 $352 $106–$1,054 $132
2022 $1,199 $448 $129–$1,270 $149
2023 $1,225 $533 $150–$1,390 $160
2024 $1,378 $605 $160–$1,606 $164
2025 $1,134 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,870 88 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $742 38 payments
  3. Janssen Biotech, Inc. $739 41 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $438 22 payments
  5. Regeneron Healthcare Solutions, Inc. $275 14 payments
  6. Celgene Corporation $255 15 payments
  7. E.R. Squibb & Sons, L.L.C. $221 2 payments
  8. Ardelyx, Inc. $216 10 payments
  9. Intercept Pharmaceuticals, Inc. $202 7 payments
  10. Pfizer Inc. $143 9 payments
  11. Other $1,297 55 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,377 300 payments
  2. Education $22 1 payment
Products named General payments · program years 2019–2025
  1. RINVOQ $1,000 43 payments
  2. STELARA $751 38 payments
  3. SKYRIZI Immunology $719 32 payments
  4. ENTYVIO $676 34 payments
  5. HUMIRA $474 28 payments
  6. ZEPOSIA $462 16 payments
  7. SIMPONI $372 22 payments
  8. SIMPONI ARIA $327 19 payments
  9. REMICADE $273 16 payments
  10. SKYRIZI Immunology $267 12 payments
  11. Other $3,092 156 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

426

Median for Gastroenterology: 569

Drug cost

$48,026

Median for Gastroenterology: $104,976

Branded share of claims

36.6%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trulance Plecanatide Brand 14 $16,979
Linzess Linaclotide Brand 14 $13,392
Mesalamine Generic 13 $5,953
Mesalamine Dr Mesalamine Brand 11 $3,301
Colestipol Hcl Generic 27 $2,350
Omeprazole Generic 93 $1,595
Pantoprazole Sodium Generic 91 $1,557
Dicyclomine Hcl Generic 14 $983
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 71 $903
Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 22 $295

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$243,409

Of which drugs: $123,443

Medicare patients

449

Average age 74

Services billed

7,933

265 women, 184 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 29%
Ischemic heart disease 28%
Depression 27%
Chronic kidney disease 23%
Atrial fibrillation 21%
COPD 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $278
$278 — —
RINVOQ
  • AbbVie, Inc. $194
$194 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $84
  • GENZYME CORPORATION $53
$137 — —
LINZESS
  • Ironwood Pharmaceuticals, Inc $78
  • AbbVie, Inc. $35
$113 14 —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $113
$113 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

301 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record